908245-03-4

Basic information

• Product Name: 6-Methyl-3piperidinecarboxylic acid Methyl ester
• Synonyms: 6-Methyl-3piperidinecarboxylic acid Methyl ester;ethyl 6-Methylpiperidine-3-carboxylate;Methyl 6-Methylpiperidine-3-carboxylate
• CAS NO: 908245-03-4
• Molecular Formula: C₈H₁₅NO₂
• Molecular Weight: 157.2102
• Mol File: 908245-03-4.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 205.9±33.0 °C(Predicted)
• Appearance: /
• Density: 0.982±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 9.47±0.10(Predicted)
• CAS DataBase Reference: 6-Methyl-3piperidinecarboxylic acid Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Methyl-3piperidinecarboxylic acid Methyl ester(908245-03-4)
• EPA Substance Registry System: 6-Methyl-3piperidinecarboxylic acid Methyl ester(908245-03-4)

Safety Data

• Hazardous Substances Data: 908245-03-4(Hazardous Substances Data)

Usage

General Description

6-Methyl-3piperidinecarboxylic acid Methyl ester is a chemical compound that consists of a piperidine ring with a methyl group attached to the 6th carbon atom and a carboxylic acid functional group at the 3rd position. The methyl ester group is attached to the carboxylic acid, making it a derivative of the parent compound. This chemical has potential pharmaceutical applications due to its structural similarity to other biologically active compounds. It may be used in the synthesis of other organic compounds or as a precursor in the production of pharmaceutical drugs or research chemicals.

Upstream product

• 5470-70-2 Methyl 6-methylnicotinate 

Downstream Products

• 1009376-87-7 methyl (3RS,6RS)-6-methylpiperidine-3-carboxylate 

Relevant articles and documents

HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF FIBROTIC DISEASE

The present invention relates to a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof and to pharmaceutical compositions comprising a compound of formula (I), as well as to the use of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, in the treatment of fibrotic diseases, preferably idiopathic pulmonary fibrosis (IPF) or non-alcoholic steatohepatitis (NASH). Further aspects of the present invention include combination therapies in which a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, is used in combination with a known anti-fibrotic or anti-inflammatory agents for fibrotic diseases.

JAK INHIBITOR

The present invention discloses a series of JAK inhibitors, and particularly discloses a compound of formula (I) or a pharmaceutically acceptable salt thereof and the use thereof in preparation of drugs for treating diseases related to JAK.

COGNITION ENHANCING COMPOUNDS AND COMPOSITIONS, METHODS OF MAKING, AND METHODS OF TREATING

The invention relates generally to muscarinic agonists, which are useful for stimulating muscarine, receptors and treating cognitive disorders. Included among the muscarinic agonists disclosed herein are oxadiazole derivatives compositions, and preparations thereof. Methods of synthesizing oxadiazole compounds also are provided. This disclosure also relates in part to compositions for enhancing cognitive function in subjects such as humans. The compositions comprising a muscarinic agonist or a pharma.ceutically suitable form thereof. This disclosure relates in part to methods of treating animals such as humans by administering such compositions.